BNP/CALL/EDWARDS LIFESCIENCES/120/0.1/19.12.25 | Real-time Boerse Frankfurt Warrants 12:05:14 2024-05-17 EDT | ||
| 0.64 EUR | -5.88% |
|
| Current month | +30.77% | ||
| 1 month | -16.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.64 | -5.88% |
| 24-05-16 | 0.68 | +4.62% |
| 24-05-15 | 0.65 | +22.64% |
| 24-05-14 | 0.53 | +1.92% |
| 24-05-13 | 0.52 | -5.45% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 12:05 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
BNP Paribas
|
| WKN | PC5C2Z |
| ISIN | DE000PC5C2Z4 |
| Date issued | 2024-02-21 |
| Strike | 120 $ |
| Maturity | 2025-12-19 (581 Days) |
| Parity | 10 : 1 |
| Emission price | 0.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.03 € |
|---|---|
| Lowest since issue | 0.5 € |
| Spread | 0.02 € |
| Spread % | 3.08% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
90.11
USD
Average target price
95.9
USD
Spread / Average Target
+6.43%
- Stock Market
- Warrants
- Warrant
